All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, August 16, 2022
Home » Topics » Disease categories and therapies » Immune

Immune
Immune RSS Feed RSS

Lymph nodes

Genetic findings pave way to treatment of lymph disorder

March 7, 2022
By John Fox
No Comments
An international collaboration led by scientists at The University of South Australia, SA Pathology in Adelaide, and the de Duve Institute, University of Louvain, Belgium, has discovered biallelic MDFIC pathogenic variants underlying the severe lymphatic disorder, central conducting lymphatic anomaly (CCLA), in seven people from six separate families.
Read More
Stomach and esophagus

Infection in thymus causes autoimmunity in stomach

March 3, 2022
By Anette Breindl
No Comments
In the February 28, 2022, issue of the Journal of Experimental Medicine, researchers from Washington University in St. Louis have demonstrated that in a mouse model, there is a causal link between murine roseolovirus and autoimmune gastritis.
Read More
Peanut allergy
Newco news

Prota Therapeutics achieves clinical remission of peanut allergy in phase IIb trial

March 1, 2022
By Tamra Sami
No Comments
PERTH, Australia – Prota Therapeutics Ltd.’s lead candidate PRT-120 induced clinical remission of peanut allergy in 51% of children in a phase IIb clinical trial. There are currently no curative therapies to treat food allergies, Prota Therapeutics CEO Mimi Tang told BioWorld. Peanut allergy in children can be particularly problematic because the only treatment is avoidance.
Read More
Hands holding arrow-shaped puzzle pieces

Huadong acquires Asia rights to drugs from Kiniksa in $662M deal

March 1, 2022
By Doris Yu
No Comments
Huadong Medicine Co. Ltd.’s wholly owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has acquired Asia-Pacific rights to two drugs from Kiniksa Pharmaceuticals Ltd. in a deal worth up to $662 million. “This collaboration aims to bring Kiniksa’s therapeutics to patients in the Asia Pacific Region suffering from severe autoimmune and inflammatory diseases,” said Sanj Patel, chairman and CEO of Kiniksa. “The collaboration also provides nondilutive capital, cost-sharing, and resources for clinical trials to accelerate our drug development and commercialization efforts.”
Read More

Conference data for Feb. 28, 2022: AAAAI

Feb. 28, 2022
No Comments
New and updated preclinical and clinical data presented by biopharma firms at the ASCO Genitourinary Cancers Symposium, including: Amgen, Knopp, Regeneron, Sanofi.
Read More

Huadong acquires Asia rights to drugs from Kiniksa in $662M deal

Feb. 25, 2022
By Doris Yu
No Comments
Huadong Medicine Co. Ltd.’s wholly owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has acquired Asia-Pacific rights to two drugs from Kiniksa Pharmaceuticals Ltd. in a deal worth up to $662 million. “This collaboration aims to bring Kiniksa’s therapeutics to patients in the Asia Pacific Region suffering from severe autoimmune and inflammatory diseases,” said Sanj Patel, chairman and CEO of Kiniksa. “The collaboration also provides nondilutive capital, cost-sharing, and resources for clinical trials to accelerate our drug development and commercialization efforts.”
Read More
Hand holding dollar sign

Scipher nabs $110M for precision medicine platform for autoimmune disorders

Feb. 24, 2022
By Annette Boyle
No Comments
It’s no mystery why Scipher Medicine Corp. successfully raised $110 million in a series D financing round to further develop the company’s precision medicine platform. The company aims to address one of most modern medicine’s most challenging enigmas: how to eliminate the cost and adverse effects associated with the prescription of expensive medications that provide life-changing outcomes for some and no benefit for others. The new funds boost Scipher’s total funding to $227 million, of which $192 million has come into the Waltham, Mass.-based company’s coffers in the last 12 months.
Read More
Peanut allergy
Newco news

Prota Therapeutics achieves clinical remission of peanut allergy in phase IIb trial

Feb. 23, 2022
By Tamra Sami
No Comments
PERTH, Australia – Prota Therapeutics Ltd.’s lead candidate PRT-120 induced clinical remission of peanut allergy in 51% of children in a phase IIb clinical trial. There are currently no curative therapies to treat food allergies, Prota Therapeutics CEO Mimi Tang told BioWorld. Peanut allergy in children can be particularly problematic because the only treatment is avoidance.
Read More
Single strand RNA

Remix RNA modulators draw $45M backing from Janssen for immunology, oncology targets

Feb. 17, 2022
By Michael Fitzhugh
No Comments
Remix Therapeutics Inc., a company developing small molecules to manipulate RNA processing, stands to earn upward of $1 billion through a new strategic collaboration with Janssen Pharmaceutica NV. A Cambridge, Mass.-based startup, Remix last year patented new RNA splicing modulators. It will receive an initial payment of $45 million for research funding plus potential preclinical, clinical, commercial and sales milestone payments, and royalties. Janssen gains exclusive rights to three targets with applications in immunology and oncology.
Read More
Skin irritation on hands

Balance beam: Third Harmonic’s start value high in KIT, scores $105M series B

Feb. 16, 2022
By Randy Osborne
No Comments
Third Harmonic Bio Inc. CEO Natalie Holles said the company’s $105 million in series B money will push THB-001 – a first-in-class, highly selective, oral inhibitor of wild-type KIT – “well past the first proof-of-concept study in inducible urticaria [hives].”
Read More
Previous 1 2 3 4 5 6 7 8 9 … 23 24 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 15, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 15, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing